Given the recent success of Treg-directed therapies, including low-dose IL-2 in SLE, and as more clinical trials move into phase 2 and 3 (49, 50), a key unanswered question is how Treg function and IL-2 homeostasis are restored. Here, IL2 is linked to systemic lupus erythematosus.